Aug 20 |
Eli Lilly's Famed Obesity/Diabetes Treatment Tirzepatide Shows Potential To Cut Risk Of Developing Diabetes, Sustained Weight Loss Over 3 Years
|
Aug 20 |
Eli Lilly Says Phase 3 Data Show Tirzepatide Cuts Risk of Developing Type 2 Diabetes
|
Aug 20 |
Eli Lilly Says Weight-Loss Drug Sharply Reduces Diabetes Progression
|
Aug 20 |
GLP-1R market: a two-horse race
|
Aug 20 |
Lilly’s tirzepatide cuts diabetes risk, study data show
|
Aug 20 |
Eli Lilly’s tirzepatide cuts risk of diabetes by 94% in obese patients
|
Aug 20 |
AstraZeneca Is a Cancer Leader. Obesity Could Be a Bonus.
|
Aug 20 |
Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight
|
Aug 19 |
Sell-Offs Didn't Scare Funds Off Amazon Stock, These Others
|
Aug 19 |
Ozempic, GLP-1 drugs are raising insurance costs. Here's why
|